Population-scale genomic medicine with the Hong Kong Genome Project
Sequencing 20,000 people reveals genomic medicine can help diagnose rare diseases in Chinese populations that European-only panels often miss.
The Hong Kong Genome Project sequenced over 20,000 participants, achieving a 25% diagnostic yield in suspected rare disease cases and demonstrating that existing European-ancestry genomic panels miss 38 clinically relevant genes for the Chinese population. Pharmacogenomic analysis found nearly universal actionable variant burden, with implications for nearly one million annual prescriptions in Hong Kong.
What the study was
- Study design
- Large-scale observational cohort with genomic sequencing (N>20,000)
- Population
- Hong Kong Chinese population: 2,227 rare disease patients + 18,261 population screening participants
- Sample size
- 20488
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Nat Med
Why it surfaced
Landmark Nature Medicine population-scale genomic cohort from underrepresented Chinese population. 25% rare disease diagnostic yield. Identification of 38 population-specific clinically actionable genes missing from European panels. Near-universal pharmacogenomic actionability. Blueprint for precision medicine in non-European populations.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.